Collectively, these results indicate that RARα-high AML cases are enriched for monocytic features associated with resistance to venetoclax-based therapies, and instead they are highly sensitive to tamibarotene and azacitidine combination. This evidence concerns the gene RARA and acute myeloid leukemia.